Page 137 - PCC10

Strengths
• Novel, first in human
• Listing of several separately categorized
adverse events
• Validated questionnaires
• Thorough treatment prior to inclusion
• Detailed cell characterization
• No drop outs
IFD‐Grand Solutions 2017‐Sheikh/CVR
Current phase III trial
• Randomized double blinded placebo controlled trial started february 2018
– 18 months post RP
– Urine continent
– Only nerve sparing procedures
– Normal erectil function pre‐RP
– Objectiv meassure of erectile function
– Mechanism of action IFD‐Grand Solutions 2017‐Sheikh/CVR
Page 131 of 135
PRECONGRESS COURSE 10 I BARCELONA, SPAIN – 1 JULY 2018 137